Target RWE’s Post

🔍 Another great presentation highlighting the exciting data at the American College of Gastroenterology 2024 on how specific medications are impacting patients with #MASLD. This research from the #TARGETNASH cohort is paving the way for better treatments and improved patient outcomes! 📽️ Watch Dr. Barritt's full presentation here: https://lnkd.in/e_CcmDX8 #LiverResearch #ClinicalInnovation #RealWorldData #PatientOutcomes #HealthcareAdvances #TargetRWE #ACG2024

Effective atopic dermatitis (AD) management goes beyond just therapy selection—patient engagement and shared decision-making are crucial. In this educational program, leading experts emphasize the importance of integrating patient preferences and goals into clinical decisions. This collaborative approach ensures that AD treatment aligns with individual patient needs, fostering better outcomes and satisfaction. In their insightful discussion, these experts also examine novel therapies targeting IL-13 and explore how emerging treatment strategies can both relieve symptom burden and improve quality of life for AD patients. Empower yourself with knowledge today: https://ow.ly/oXLZ50QLPH1 #AtopicDermatitis #MedicalEducation #IL13

Casey Butrus, PharmD; Michael Cameron, MD FAAD; and Brittany Craiglow, MD, provide insights on the differences between therapies that require continuous use versus those that can be intermittently used for atopic dermatitis (AD). The experts explore the potential of combination therapy and discuss optimal efficacy and duration of therapy regimens to maximize patient outcomes. Watch the #PayerPerspectives episode here: https://bit.ly/4dQxuuf #AtopicDermatitis

It’s https://hubs.ly/Q02nP2Rr0 Feature Friday: Did you know that the UroLift System is supported by clinical results from over 145 peer-reviewed publications? The Clinical Results page makes it easy for you to review the data that explains why the UroLift System is the #1 minimally invasive BPH treatment chosen by urologists.* Visit https://hubs.ly/Q02nPgTB0. *U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/warranties, including accuracy or completeness.

Just published 📖 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗼𝗻𝘀𝗲𝗻𝘀𝘂𝘀 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗩𝗲𝗻𝗼𝘂𝘀 𝗟𝗲𝗴 𝗨𝗹𝗰𝗲𝗿𝘀 (𝗩𝗟𝗨𝘀) Recently published in Wound Care Canada and developed by a diverse panel of experts, the Consensus Statement is an up-to-date practical guide for health-care providers managing patients with VLUs. The guide incorporates the latest clinical research, including the use of muscle pump activators (MPAs,) such as The geko® device, which significantly improve healing rates and patient outcomes. Key highlights include diagnosis and assessment of VLU’s, VLU treatment strategies, effective wound care recommendations and emphasis on patient education and prevention of recurrence. Click here for the Consensus Statement: https://lnkd.in/eG5hducz And here to learn more about the geko device: https://lnkd.in/e-6tnSp2

Join us for our upcoming webinar, Management of Dermatomyositis: Focus on IG Therapy. In this live educational webinar sponsored by Octapharma, Dr. Christina Charles-Schoeman will discuss intravenous immunoglobulin (IVIg) therapy for adults with dermatomyositis (DM). Learn how IVIg therapy works, how it affects patient outcomes, and why it's important for patients to understand IVIg within the current treatment paradigm. The webinar will be followed by a Q&A session. Find all the details and register today! https://lnkd.in/e3fSF3Ff #Myositis #MyositisWarrior #MyositisAwareness #TheMyositisAssociation #MyositisSupport #RareDisease #MYOMovement #MyositisLife #MyTMA #PatientAdvocacy #TheMyositisAgenda

Unlocking new horizons in critical care, Cytosorb emerges as a pivotal player in managing hyperbilirubinemia. Elevating patient care standards, this breakthrough technology efficiently removes bilirubin and toxins from the bloodstream. Hyperbilirubinemia, a condition characterized by elevated bilirubin levels, poses significant challenges in conditions like liver dysfunction and hemolysis. Cytosorb's innovative hemoadsorption capability intercepts bilirubin as blood flows through, alleviating symptoms such as jaundice and pruritus while mitigating potential neurological complications. Integrated seamlessly into treatment regimens, especially in acute liver failure or sepsis-associated liver dysfunction scenarios, Cytosorb complements comprehensive approaches, offering vital support to liver function and enhancing patient outcomes. As research expands and clinical insights deepen, Cytosorb's versatility in managing hyperbilirubinemia underscores its transformative potential in critical care. Healthcare professionals harness its power to tailor treatment strategies, ensuring optimal patient care. Explore the frontier of critical care with Cytosorb and revolutionize patient outcomes. #Cytosorb #CriticalCare #HyperbilirubinemiaManagement #InnovativeTechnology #PatientCareExcellence

💡 New AASLD practice guidance highlights the key role of FibroScan® in aiding in both the identification of patients who may be eligible for resmetirom and assessing response to therapy. Liver stiffness measurement (LSM) by VCTE™ is recommended:  • For patient selection, to help identify MASH patients with F2-F3, with suggested LSM range between 8 and 15 to 20 kPa.  • To exclude patients with evidence of compensated/decompensated cirrhosis who should not be considered for treatment, including those when LSM ≥20 kPa. • To utilize changes in LSM in combination with other clinical factors to assess treatment response at 12 months. ⭐ FibroScan® is a recommended option for patient selection and therapeutic monitoring to support clinical decision-making. By advancing non-invasive liver health management, we’re helping to deliver better patient outcomes with resmetirom therapy and beyond. #LiverHealth #LiverHealthMatters #FibroScan Link to AASLD guidance: https://lnkd.in/euxRkSUE 

Just published 📖 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗖𝗼𝗻𝘀𝗲𝗻𝘀𝘂𝘀 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗩𝗲𝗻𝗼𝘂𝘀 𝗟𝗲𝗴 𝗨𝗹𝗰𝗲𝗿𝘀 (𝗩𝗟𝗨𝘀) Recently published in Wound Care Canada and developed by a diverse panel of experts, the Consensus Statement is an up-to-date practical guide for health-care providers managing patients with VLUs. The guide incorporates the latest clinical research, including the use of muscle pump activators (MPAs,) such as The geko® device, which significantly improve healing rates and patient outcomes. Key highlights include diagnosis and assessment of VLU’s, VLU treatment strategies, effective wound care recommendations and emphasis on patient education and prevention of recurrence. Click here for the Consensus Statement: https://lnkd.in/eG5hducz And here to learn more about the geko device: https://lnkd.in/e-6tnSp2

Join us at #AES2024 for an expert-led symposium on prioritizing seizure treatments through real-world patient case studies. SK Life Science Inc.’s Symposium taking place on 12/6 at 6pm PST will discuss:   👉 Understanding the unmet need for achieving seizure freedom and identifying patients who may need treatment modifications  👉 The impact of continued seizures on patients and their treatment journeys  👉 How treatment regimens may be optimized to provide early efficacy, increase the likelihood of seizure freedom, and decrease the number of concomitant medications